Ingelise Saunders takes over as CEO of SLS Invest
This article was originally published in Scrip
Executive Summary
Ingelise Saunders has been appointed CEO of SLS Invest to take the place of Per Carendi who is retiring after four years in the role. Ms Saunders' previous positions include CEO of ACE BioSciences and CEO of Celltech Pharmaceuticals. She is currently CEO of Action Pharma, one of SLS Invest's portfolio companies and serves on the board of Topotarget.